Calypso Biotech SA
Immunotherapy biotech company that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs.
The Portfolio consists of two preclinical therapeutic antibodies that intercept key immune checkpoints involved in multiple immune pathologies.
Calypso Biotech targets diseases which incidence has dramatically increased in recent years due to changes in diet and lifestyle, likely through alteration of the microbiome.
Primary Therapeutic Areas
1.0 Therapeutic & Diagnostic
1.00 Antibodies & Anti-infectious
1.09 Proteins & Peptides
Endocrine & Metabolic, Immunology & Allergy
Chemin des Aulx 14
1228 Plan-les-Ouates / GE